This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).
Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View
by Zacks Equity Research
Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.
New Batch of Q3 Earnings: AMZN, GOOGL, INTC & More
by Mark Vickery
Big afternoon of new quarterly earnings releases after the bell today, with some of the world's largest technology firms hitting the tape.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 10.84% and 2.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.
Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.
Earnings Keep Pouring In: Global Week Ahead
by John Blank
So far, almost 90% of the firms have beaten analysts' earnings expectations. About 70% have beaten revenue expectations. This week, 156 S&P 500 firms release earnings.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.17, marking a -1.92% move from the previous day.
Gilead Sciences (GILD) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.24, marking a -0.24% move from the previous day.
Merck Reports Positive Efficacy Data from Phase III HIV Study
by Zacks Equity Research
Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
Gilead Announces Positive Data From Ongoing Biktarvy Study
by Zacks Equity Research
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
by Zacks Equity Research
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.